New York, NY, and Tel Aviv, ISRAEL, June 3, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its academic partner, Dr. Thomas Arendt of the University of Leipzig, has completed full enrollment of the 2nd (confirmation) cohort for the ongoing clinical trial to assess the concordance of LymPro Alzheimer blood test scores with amyloid PET imaging scores. The Company expects the data to be released in the summer of 2022.
The Lymphocyte Proliferation Test (LymPro Test™) determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that prompts them to enter the cell cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised cellular machinery that leads to aberrant cell cycle reentry by neurons, which then leads to apoptosis. LymPro is unique in using peripheral blood lymphocytes as surrogates of neuronal cell function, suggesting a common relationship between PBLs and brain neurons.
About Alzheimer’s disease
According to the Alzheimer’s Association, it is estimated that more than 5.4 million people in the United States suffer from Alzheimer’s disease. More than 500,000 patients are diagnosed each year, with nearly one in eight older Americans affected by the disease. Alzheimer’s disease is the third leading cause of death in the United States. The cost of unpaid care in the United States is estimated at more than $210 billion per year. Total payments for care are estimated at more than $200 billion a year, including $140 billion in costs for Medicare and Medicaid. Spending on Alzheimer’s disease in the United States is expected to exceed $1.2 trillion by 2050. There is no cure or effective treatment for Alzheimer’s disease. Worldwide, approximately 35.6 million people have the disease and, according to the World Health Organization, this number will double every 20 years to reach 115.4 million people with Alzheimer’s disease. 2050.
About Dr. Arendt’s research at the University of Leipzig
Dr. Thomas Arendt is Professor of Neuroscience at the University of Leipzig, where he directs the Paul Flechsig Institute for Brain Research. He has 30 years of experience in R&D of therapeutic and diagnostic strategies for neurodegenerative disorders and has made several fundamental contributions to Alzheimer’s disease therapeutic concepts, including stem cell therapy and tumor suppressor gene modulation. In the early 1980s, he helped identify the degeneration of the cholinergic system in Alzheimer’s disease, laying the foundations for the only treatment available today. He is one of the pioneers of the “cell cycle theory” of Alzheimer’s disease, which he developed into a diagnostic and therapeutic concept.
About Todos Medical Ltd.
Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs life-saving diagnostic solutions for the early detection of various cancers. The company’s advanced and patented Biochemical Infrared Assays (TBIAs) are a proprietary cancer screening technology using peripheral blood analysis that deploys an in-depth examination of cancer’s influence on the immune system, looking for biochemical changes in blood and plasma mononuclear cells. The two cancer screening tests developed in-house by Todos, TMB-1 and TMB-2, have received CE marking in Europe. Todos recently acquired US medical diagnostics company Provista Diagnostics, Inc. to obtain the rights to its Alpharetta, Georgia-based CLIA/CAP-certified laboratory, which currently performs COVID PCR tests and the breast cancer screening blood test. Videssa® exclusive to Provista at the commercial stage.
Todos also develops blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that prompts them to enter the cell cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised cellular machinery that leads to aberrant cell cycle reentry by neurons, which then leads to apoptosis. LymPro is unique in using peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and brain neurons.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover several international suppliers of PCR test kits and related equipment and supplies, as well as antibody test kits from several manufacturers after completing validation of said test kits and supplies at its CLIA/CAP certified partner laboratory in United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based solely on the current expectations of management and are subject to important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties relating to the progress , timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional financing required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in the initiation of our clinical trials; changes in legislation; failure to develop and introduce new technologies, products and applications on a timely basis; lack of validation of our technology as we progress and lack of acceptance of our methods by the scientific community; the inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may arise with our process; cost of final product higher than expected; loss of market share and pressure on prices resulting from competition; and laboratory results that do not translate into equally good results under actual conditions, which could cause actual results or performance to differ materially from those contemplated by such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please see its reports filed from time to time with the United States Securities and Exchange Commission.
917-983-4229 ext. 104
Investor Relations contact: